Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cyclopentolate + phenylephrine is a fixed-dose combination ophthalmic solution used to induce mydriasis (pupil dilation) for diagnostic eye examinations. Cyclopentolate is an anticholinergic agent that relaxes the sphincter muscle of the iris, leading to pupil dilation and some paralysis of accommodation (cycloplegia). Phenylephrine is an adrenergic agonist that stimulates alpha-1 adrenergic receptors in the dilator muscle of the iris, causing further pupil dilation through vasoconstriction. The combination provides greater mydriatic effect than either drug alone at their respective concentrations, with minimal cycloplegia. It is commonly used prior to eye exams or procedures requiring a dilated pupil[1][2][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cyclopentolate + phenylephrine.